Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 12:45 am
Share
Amicogen, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 815.98 million compared to KRW 946.13 million a year ago. Net income was KRW 500.09 million compared to net loss of KRW 20,758.86 million a year ago. Basic earnings per share from continuing operations was KRW 25 compared to basic loss per share from continuing operations of KRW 1,071 a year ago. Diluted earnings per share from continuing operations was KRW 25 compared to diluted loss per share from continuing operations of KRW 1,044 a year ago. Basic earnings per share was KRW 25 compared to basic loss per share of KRW 1,071 a year ago.
For the nine months, sales was KRW 2,569.75 million compared to KRW 3,246.87 million a year ago. Net loss was KRW 19,324.84 million compared to net income of KRW 24,220.9 million a year ago. Basic loss per share from continuing operations was KRW 978 compared to basic earnings per share from continuing operations of KRW 1,257 a year ago. Diluted loss per share from continuing operations was KRW 978 compared to diluted earnings per share from continuing operations of KRW 1,255 a year ago. Basic loss per share was KRW 978 compared to basic earnings per share of KRW 1,257 a year ago.
Amicogen, Inc. is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâs products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company distributes its products within domestic market and to overseas markets, including China, Japan, the United Sates, Germany and Thailand.
AMICOGEN, INC. 